Purpose: Taste and smell alterations (TSAs) are common symptoms in patients with cancer that may interfere with nutritional intake and quality of life. In this study, we explore and describe how characteristics of self-reported TSAs change in individuals with lung cancer over time using a multiple case study approach to present longitudinal data from individuals. Methods: Patients under investigation for lung cancer were recruited from one university hospital in Sweden. The 52 patients providing data eligible for the analyses presented here were those treated for primary lung cancer with three measurement time-points, of which one was prior to treatment and two after treatment start. Four self-report instruments were used for data collection. These included the Taste and Smell Survey, used to characterize TSAs for each individual at the three time-points and instruments measuring nutritional status, symptom burden and well-being. Three patient cases are described in detail to illustrate variation in individual experiences of TSAs. Results: The characteristics of the TSAs experienced changed over time for many of the individuals in this study, including those undergoing surgery or stereotactic radiotherapy. The case descriptions show how the individual experiences of TSAs and the impact on daily life of these symptoms not only depend on TSA characteristics, but may be influenced by contextual factors, e.g. other symptoms and life situation. Conclusions: Our results suggest that healthcare professionals need to consider the variation in characteristics of TSAs among and within patients over time, and be attentive to individual experiences of TSAs.
Introduction
Taste and smell alterations (TSAs) are recognized as common symptoms in patients with cancer that may interfere with nutritional intake and quality of life (Hutton et al., 2007; Zabernigg et al., 2010) . Although TSAs have most often been studied in relation to cancer treatments such as chemotherapy and radiotherapy to the head-neck area, they have also been reported at the time of diagnosis and in palliative phases of cancer Hutton et al., 2007; Yamashita et al., 2006) .
One research strategy to assess taste function is to clinically test recognition and detection thresholds of the basic taste qualities (sweet, sour, salt, bitter and umami) or odours (Wismer, 2008) . However, in the Swedish study presented here we were interested in patients' experiences of TSAs rather than their taste and smell acuity and we therefore used a self-report instrument to Abbreviations: ESAS, Edmonton Symptom Assessment System; FAACT, Functional Assessment of Anorexia-Cachexia Therapy; M1, measurement time-point before treatment start; M2, first measurement time-point after treatment start; M3, second measurement time-point after treatment start; PG-SGA SF, Short form of Patient-Generated Subjective Global Assessment; SRT, stereotactic radiotherapy; TSA, taste and smell alteration; TSS, Taste and Smell Survey.
investigate TSAs in patients treated for lung cancer. Recent research has acknowledged the lack of consensus surrounding the concepts and words used for describing altered taste and smell experiences during cancer (Boltong and Keast, 2015) . For instance, 'taste' is often confused with flavour making it difficult to differentiate these concepts. Furthermore, flavour is a term which does not exist in the Swedish language. Based on that and in line with previous research (Bernhardson et al., 2008a; Steinbach et al., 2009; we have used the words "taste" and "taste and smell" in their colloquial sense to encompass flavour, taste and/or smell. When we refer to the sense of taste in terms of the basic taste qualities, we use the term "basic taste".
Prior longitudinal studies of TSAs have shown that, at group level, mean intensity scores of self-reported taste changes measured on a 4-point Likert scale, increase during the patient's course of chemotherapy Zabernigg et al., 2010) . Steinbach et al. (2009) provided complementary information by clinically testing senses of taste and smell, and found, also at group level, increasingly impaired basic taste and smell function during chemotherapy. Similar results were presented by Boltong et al. (2014) , who found an overall reduced taste function in patients undergoing chemotherapy and a cyclical change associated with proximity to chemotherapy administration; however they also reported taste function being restored eight weeks after completed chemotherapy. In a qualitative study by Bernhardson et al. (2007) , patients undergoing chemotherapy were interviewed about their TSAs. They found that problems with taste and smell improved gradually after completed treatment, ceasing completely after 0.5e14 weeks. Brisbois et al. (2011) addressed differences in qualities of TSAs by grouping patients according to self-reported increased or decreased sensitivity to basic taste qualities (sweet, salt, sour and bitter) or smell. Our recent research developed this further to also account for self-reported TSAs that do not involve intensity changes, such as metallic taste or reduced enjoyment of specific foods . In that cross-sectional study, we observed gender differences among the groups describing different TSA qualities.
Although studies of groups of patients present important information about TSAs in patients with cancer, they do not reveal the nature of the individual experiences underlying group averages. Systematic study of individual experiences of TSAs may thus provide information of particular relevance for healthcare professionals dealing with symptomatic individuals in their daily practice. In addition, while the previously mentioned longitudinal studies using symptom intensity scoring provide descriptive information about some central aspects of TSAs, they do not give insight into other types of changes in taste and smell. Few studies to date have investigated the many different qualities of perceived TSAs, such as increased or decreased sensitivity in basic taste qualities or smell, and longitudinal data on this is particularly lacking. It is also important to consider that many of the different qualities of TSAs are not mutually exclusive, as an individual patient can experience several changes simultaneously.
This complexity led us to recognize that our previous results McGreevy et al., 2014) did not adequately represent patients' individual experiences of TSAs. In the study presented here, we address these knowledge gaps by exploring and describing how characteristics of TSAs change in individuals treated for lung cancer over time. For this purpose, we have chosen a multiple case study design (Yin, 2014) , allowing the combination of complementary data types to further understanding of individuals' experiences of TSAs.
Methods
The data presented here derive from the longitudinal "Taste and Smell project" which was approved by the Regional Ethical Review Board, Stockholm (2009 Stockholm ( /1463 /1849 2011 /1324 .
Patients and data collection procedure
Patients under investigation for lung cancer were recruited consecutively between January 2011 and July 2012 from one university hospital in Stockholm, Sweden. Patients were informed about the study by a staff nurse during their first visit at the outpatient clinic. If patients expressed interest in study participation, their contact information was forwarded to the researchers who contacted them by telephone. After a patient had agreed to participate and provided informed consent, one of four interviewers (either a nurse or dietitian) carried out structured faceto-face interviews based on the four questionnaires described below. Patients were first interviewed before treatment start, with three follow-up interviews conducted thereafter at two-month intervals. When feasible, the same interviewer conducted all interviews, reading the questions aloud and documenting the patient's responses. After each interview, the research interviewer compiled field notes with information about the context of the interview and other details of importance beyond that documented in the questionnaires. Additional clinical and background information was obtained from medical records with patients' consent.
Data for the analyses presented here were derived from patients participating in the "Taste and Smell project" who were treated for primary lung cancer, and had documented interviews conducted at a minimum of three of the four measurement time-points. Patients' treatment modalities were dichotomized as those receiving 1) systemic therapy, i.e. targeted therapy or chemotherapy, including concomitant chemo-radiotherapy, and adjuvant chemotherapy after surgery; or 2) localized therapy, i.e. surgery or stereotactic radiotherapy (SRT). Treatment start was registered as the first day of the targeted therapy or first chemotherapy cycle, day of surgery or first day of SRT.
In this study, the first measurement time-point, here referred to as M1, was held before treatment start. The second measurement time-point (M2) took place within 30e99 days after treatment start, so that patients on chemotherapy should have received at least two of their planned treatment cycles. The third measurement time-point (M3) took place 100 days after treatment start, to avoid overlap between time frames for M2 and M3. The exact number of days between measurement time-point and the previous treatment for individual patients is not presented here as the purpose of this study is to explore and describe changes in characteristics of TSAs rather than establish patterns of effects of cancer treatment on TSAs.
Questionnaires
The four self-report instruments used for data collection were presented in the same order to all patients.
The first instrument was the Swedish version of The Taste and Smell Survey (TSS) (Heald et al., 1998; McGreevy et al., 2013) . The TSS is a 16-item TSA symptom-specific questionnaire, originally developed for patients with HIV, but used in research settings with patients with cancer in both Canada (Bernhardson et al., 2012; Brisbois et al., 2011; Hutton et al., 2007) and Sweden McGreevy et al., 2013) . The TSS consists both of items with fixed response alternatives and open-ended items to explore perceived changes in taste and smell sequentially.
The second self-report instrument was the Edmonton Symptom Assessment System (ESAS) (Bruera et al., 1991) , which uses visual analogue scales to assess nine symptoms: pain, tiredness, nausea, depression, anxiety, drowsiness, loss of appetite, shortness of breath and "other". An additional item assesses general well-being. Higher scores indicate greater symptom intensity.
The third instrument, the Functional Assessment of AnorexiaCachexia Therapy (FAACT), assesses aspects of well-being (Ribaudo et al., 2000) . Patients rate their level of agreement with each of 40 statements on a five-point Likert scale. The statements are grouped into five domains of which four concern physical, social, emotional and functional well-being, and the fifth assesses other eating-related problems.
The short form of the Scored Patient-Generated Subjective Global Assessment (PG-SGA SF) (Bauer et al., 2002; Ottery, 1996; Persson et al., 1999; Vigano et al., 2014) was the final instrument used to assess weight change, food intake at present compared to "normal", symptoms that may have interfered with food intake, and perceived physical function.
Analysis and presentation of data
Traditional scoring of the TSS results in a "chemosensory complaint score" of 0e16 (Heald et al., 1998) , with items reflecting TSAs' perceived nature and severity. In the study presented here, we seek to disentangle these different aspects of TSAs. We therefore adapted the use of TSS items and score to reflect TSA characteristics. We used seven items from the TSS addressing qualities of TSAs to categorise characteristics: five items assessing general changes in perceptions of taste or smell including persistent bad taste in mouth, and two items concerning changes in perception of intensity in four basic taste qualities (sweet, salt, sour and bitter) and/ or smell.
Using the responses to these items, patients' TSAs were categorised into five TSA intensity categories according to their reported change in perceived intensity of TSAs qualities as follows: 1) no TSAs, 2) TSAs with stronger intensity of any or all of the basic taste qualities and/or smell, 3) TSAs with weaker intensity of any or all of the basic taste qualities and/or smell, 4) TSAs with mixed changes in intensity including both stronger and weaker intensity of different basic taste qualities and/or smell, and 5) other TSAs, including those reporting general changes in perception of taste or smell, but without specification of intensity changes in basic taste qualities or smell.
An additional strategy used here to present the data on characteristics of TSAs is calculation of a summed score from the seven TSS items described above. This score reflects the number of different qualities of TSAs reported by one patient at a specific timepoint, giving an indication of what we here call the multiplicity of TSAs. The TSA multiplicity score was calculated using the standard TSS scoring, in which six items each yield either zero or one point, and one item has four sub-items and therefore yields between 0 and 4 points, giving a total TSA multiplicity score ranging between 0 and 10.
We present the case study data in two different forms. First, changes in TSA characteristics between different time-points are cumulatively explored based on each individual; this is done by graphically charting both the TSA intensity category and the TSA multiplicity score for individual patients at each time point (M1, M2 and M3). These data are presented by treatment type and gender to allow visual overview of changes over time which might facilitate hypothesis generation. For example, systemic and localized treatment might be postulated to affect TSAs through different mechanisms, and results from our previous research ) have suggested differences in TSA qualities between men and women.
We thereafter present narrative descriptions of three individual cases to provide richer information about different experiences of having TSAs in the context of a lung cancer disease and its treatment. The case descriptions were summarized using data from the interviewer's field notes, responses to open-ended questions, and answers to, or ratings of, selected items in the four questionnaires. The names used here are fictitious.
For demographic purposes, patients' smoking status was categorised as smoker, former smoker (quit >1 year ago) and non- Fig. 1 . Overview of the selection process. M, male; F, female. *Other reasons, e.g. major co-morbidities, cognitive impairments, withdrawn consent.
smoker (includes occasional smoking), based on the distinctions made by the Swedish National Lung Cancer Registry (Swedish Lung Cancer Registry Board, 2010).
Results
Of the 255 patients interviewed for the Taste and Smell Project, 52 patients met inclusion criteria with data at three time-points eligible for analysis. See Fig. 1 for an overview of the selection process. Patients' demographic and clinical characteristics are shown in Table 1 .
Individual changes in characteristics over time
Figs. 2ae5a graphically represent individual changes in TSA intensity categories over time according to gender and treatment type. Only 14 of the 52 individuals included in the study remained in the same TSA intensity category at all three timepoints, with 11 of these patients reporting no TSAs at each time-point. Eighteen individuals shifted TSA intensity category (no TSAs, stronger intensity, weaker intensity, mixed changes in intensity or other TSAs) both between M1eM2 and between M2eM3. Figs. 2be5b present the corresponding individual Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger and weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no specification in intensity changes in basic taste qualities or smell.
changes in TSA multiplicity scores over time. In general, the TSA multiplicity scores were relatively low among those who reported experiencing any TSAs. Twenty-eight of the 52 individuals in the study had TSA multiplicity scores of 0e2 at all time-points; it was only at the time-points after start of treatment (M2, M3) that seven individuals reported TSA multiplicity scores as high as 7e10. This also indicates that many of the individuals in this study reported an increase in TSA multiplicity scores after treatment start, that is between M1eM2. This was expected for the patients undergoing systemic treatment, but Figs. 2b and 3b suggest that several of the men and women treated with localized therapy also report increases in TSA multiplicity scores between M1 and M2. However, many of these individuals also report decreases in TSA multiplicity scores between M2 and M3.
Narrative case descriptions
The cases of Beata, Carl and Gunilla are described in depth in Boxes 1, 2 and 3, respectively; their reported TSA trajectories are also indicated in Figs. 3a,b (Beata), 4ae4b (Carl), and 5ae5b (Gunilla) with bold, broken lines.
Beata's case illustrates that patients may experience TSAs prior to treatment. She is one of the individuals in our study who underwent localized treatment and reported TSAs afterwards. Carl was chosen to exemplify those persons who experienced TSAs without intensity changes in basic taste qualities and smell during chemotherapy treatment. Gunilla represents a typical scenario with subtle TSAs before treatment start, but problems from alterations in both taste and smell during concomitant chemo-radiotherapy.
These three case descriptions demonstrate that the consequences Fig. 3 . a and b. Individual changes over time in characteristics of TSAs in women with localized therapy (n ¼ 11), regarding a) TSA intensity categories and b) TSA multiplicity scores (0e10). TSAs, taste and smell alterations M1, measurement time-point before treatment start; M2, first measurement time-point after treatment start; M3, second measurement time-point after treatment start No TSAs: Patients not reporting any TSAs; Stronger: Patients reporting stronger intensity in any or all of the basic taste qualities or smell; Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger and weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no specification in intensity changes in basic taste qualities or smell.
----represents Beata, see case description in Box 1. Fig. 4 . a and b. Individual changes over time in characteristics of TSAs in men with systemic therapy (n ¼ 14), regarding a) TSA intensity categories and b) TSA multiplicity scores (0e10). TSAs, taste and smell alterations M1, measurement time-point before treatment start; M2, first measurement time-point after treatment start; M3, second measurement time-point after treatment start No TSAs: Patients not reporting any TSAs; Stronger: Patients reporting stronger intensity in any or all of the basic taste qualities or smell; Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger and weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no specification in intensity changes in basic taste qualities or smell.
----represents Carl, see case description in Box 2.
of TSAs on daily life are individual, and depend not only on the characteristics of TSAs, but on an individual person and his/her general life-situation as well as other symptoms and treatment side-effects.
Discussion
Through this multiple case study approach, we are able to expand further on our previous findings about the diversity of characteristics of TSAs between individuals treated for primary lung cancer to also show that characteristics of TSAs change over time within many individuals in our study. However, our results also suggest that the individual experiences of TSAs and the impact of these symptoms on daily life may be influenced by individual and contextual factors such as other symptoms, treatment side-effects and general lifesituation.
Previous longitudinal research has also demonstrated changes in TSAs over time in relation to treatment, but studies have primarily addressed TSAs in terms of self-reported symptom intensity or as changes in thresholds of basic taste and smell function at group level (Boltong et al., 2014; Steinbach et al., 2009; Zabernigg et al., 2010) . Our results suggest that not only intensity but also the characteristics of TSAs may change over time in individuals in relation to treatment. This is important information for health-care professionals, as the characteristics of TSAs should be taken into consideration when providing guidance and advice to patients for managing TSAs. For example, a patient experiencing a general decrease in taste function would not benefit from the same recommendations as someone who is bothered by a persistent bad taste in the mouth. Few research studies to date have addressed management strategies for TSAs (Thorne et al., 2015) ; our results suggest that follow-up of patients experiencing TSAs is of critical importance in order to adjust strategies to manage TSAs according to their changing characteristics.
Based on previous research on TSAs in patients with cancer (Bernhardson et al., 2008a; Joussain et al., 2013) we anticipated that TSAs would present after start of systemic treatment. Interestingly, several of the individuals in our study undergoing localized treatment with surgery or SRT also reported perceiving TSAs after this treatment (at M2 and M3). There are research reports of patients experiencing TSAs after surgery in the headneck and gastric area (Heiser et al., 2010; Wikman et al., 2014) and a number of case reports of patients experiencing TSAs after general anesthesia (Dhanani and Jiang, 2012; Konstantinidis et al., 2009 ). The authors of these studies present theories for underlying mechanisms, which are often neurological, but also include factors such as wound healing, postoperative changes in nutritional intake, and side-effects of medications, all of which may be applicable to the patients included in our study. To the best of our knowledge, no previous study has reported changes in taste or smell following surgery for lung cancer, which might thus be a relevant topic for further investigation. Our results also show that TSAs present not only following treatment, as focused on in previous research, but also prior to treatment. This has been investigated in more detail in our previous work .
The narrative descriptions found in the three individual cases of Beata, Gunilla and Carl also suggest that although the characteristics of TSAs and changes in these, presented in Figs. 2e5a and 2e5b, reveal some aspects of the patient's individual experiences of TSAs, they do not capture the whole picture. The case reports illustrate different qualities of TSAs and the consequences of TSAs on daily life, such as impaired food enjoyment, restricted social life, and how the experience of TSAs are influenced by other symptoms and side-effects from treatment. These results are in line with previous research investigating the nature of TSAs and their impact on daily life (Bernhardson et al., 2008b; .
The case descriptions also provide additional information about the individual experience of TSAs in relation to food intake: Gunilla and Beata report similar characteristics of TSAs at the first follow-up after treatment start (M2), with both of them having TSAs with mixed changes in intensity and rather high TSA multiplicity scores of eight and seven, respectively. However their ratings on the PG-SGA SF checklist of symptoms interfering with food intake differ. Whereas Gunilla reports that TSAs along with other symptoms have affected food intake after treatment start, Beata, who also reports eating problems, instead indicates symptoms other than TSAs on this checklist. In our previous study we found that although 38% of the 117 patients prior to treatment Patients reporting stronger intensity in any or all of the basic taste qualities or smell; Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger and weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no specification in intensity changes in basic taste qualities or smell.
----represents Gunilla, see case description in Box 3.
for lung cancer reported TSAs on the TSS, as few as eight of these indicated on the PG-SGA SF checklist that "taste changes" or "being bothered by smells" had interfered with food intake . When "taste changes" or "being bothered by smells" were indicated on the PG-SGA SF symptoms checklist, it was in conjunction with loss of appetite and/or nausea, which are symptoms well known to impair food intake. This suggests that other symptoms such as loss of appetite and nausea may be more powerful drivers of reducing food intake, but that TSAs may contribute and worsen the situation when presenting with these Box 1 Case description, Beata.
other symptoms.
The interaction between TSAs and other concurring symptoms should also include mention of the hedonic aspect of foods, which can be difficult to distinguish from the purely sensory perception of basic taste and smell. Hedonics is a concept which refers to the pleasantness and unpleasantness of sensory experience, for example from the taste of foods . For instance, although different individuals may have the same sensory experience of the taste of coffee, some people enjoy it whilst others may not. The hedonic experience of foods has also been reported to encompass hunger and appetite , which adds to the complexity of food enjoyment when experiencing multiple symptoms. The case description of Carl exemplifies this, as he says that it is not really his basic taste function that has changed, but his liking of familiar foods.
The concepts used here of TSA intensity categories and TSA multiplicity score have several limitations that should be considered. The TSA intensity categories indicate the type and direction of a patient's perceived TSAs and allowed us to show how characteristics of TSAs may change over time in individual patients in relation to treatment start. However, the TSA intensity categories do not contain information about the magnitude of the changes or how bothersome they are perceived to be. Also note that for consistency in categorization of TSA data, we used a strategy where we prioritized reports of changes in perceived intensity of the basic taste qualities or smell, such that only when no such changes were reported did we use the category "other TSAs" for other reported changes. The use of the TSA intensity categories is probably not appropriate in clinical practice, as successful management of TSAs demands more detailed information about an individual patient's TSAs. The TSA multiplicity score reflects the number of different TSAs reported by one patient and allowed us to show that many individuals in our study reported a larger number of TSAs after start of treatment. Limitations here include the TSS items used not being mutually exclusive, as some are open-ended while others have fixed answer alternatives. Therefore, a patient could report the same type of change in more than one item.
In this study, we chose a multiple case study approach to focus on individuals. We do not claim that these individuals are necessarily representative of the general lung cancer population; instead Box 2 Case description, Carl.
Box 3
Case description, Gunilla.
we believe that our results demonstrate the importance of being aware of the variation of the individual symptom experience. This concerns both clinical practice and research, where individual changes may be concealed in results reported at group level. We argue that the case study approach is of particular interest for health-care professionals, as they deal with the individual experiences of disease and symptoms in their daily practice.
Conclusion
The results from this study further our understanding of cancer-related TSAs by illustrating that the characteristics of TSAs changed relative to the start of both systemic and localized therapy. Furthermore, the complexity of the individual experiences of TSAs suggest that health-care professionals should be attentive to changes in characteristics of TSAs to adapt advice and support to the individual needs and experiences of patients with TSAs.
